Funding for this research was provided by:
Cancer Research UK (C23338/A25722, C16731/A21200)
Wellcome Trust (209213/Z/17/Z)
Article History
Received: 1 December 2020
Revised: 18 January 2021
Accepted: 21 January 2021
First Online: 6 April 2021
Ethics approval and consent to participate
: Not applicable.
: All data within this article are available through the cited references.
: B.V. is a consultant for Karus Therapeutics (Oxford, UK), iOnctura (Geneva, Switzerland) and Venthera (Palo Alto, US) and has received speaker fees from Gilead (Foster City, US). The other authors declare no conflict of interest relating to this work. The authors have no additional financial interests.
: Relevant work in the B.V. laboratory is supported by PTEN Research and Cancer Research UK (C23338/A25722). The A.G. laboratory is supported by Cancer Research UK (C16731/A21200) and the Wellcome Trust (209213/Z/17/Z).